

## About

Join Steve Swann and Eric Sigel for TandemAI's first "Fireside Chat" of the year!

As a technology company dedicated to lowering the barrier to entry to the most advanced tools in drug discovery, we've been closely following the rapid emergence and applications of AI. AI continues to demonstrate significant promise in key areas of drug discovery ranging from new target identification to compound optimization, and even clinical trial design. The excitement around AI and other computational approaches has the potential to significantly increase the efficiency and success rate of drug discovery in an industry that continues to suffer from increasing costs and debilitating attrition. However, the scientific evolution of these computational tools continues to largely outpace their implementation and integration within companies across the drug discovery industry. The availability and integration of high-quality data can be a significant limitation. In addition, the adoption of these tools to drive decision making can be dependent on internal expertise and awareness, strategic implementation, and scientific and cultural alignment.

Our webinar will address the challenge of understanding the strengths and weaknesses of key computational tools to identify what is useful today and what could be impactful in the future.